Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCAR1 | Q9BXC0 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22862669 | 0.94 | HSD17B10 (0.43) | HSD17B10GAAHCAR1ALDH1A1HPGD | |
| SCHEMBL29490299 | 0.94 | HSD17B10 (0.43) | HSD17B10GAAHCAR1ALDH1A1HPGD | |
| SCHEMBL14852094 | 0.86 | DRD2 (0.45) | HSD17B10GAAALDH1A1KMT2AFLT3 | |
| SCHEMBL22862666 | 0.83 | GAA (0.50) | HSD17B10GAAHCAR1ALDH1A1HPGD | |
| SCHEMBL29490333 | 0.83 | GAA (0.50) | HSD17B10GAAHCAR1ALDH1A1HPGD | |
| SCHEMBL22862542 | 0.79 | HSD17B10 (0.40) | HSD17B10GAAHCAR1ALDH1A1HPGD | |
| SCHEMBL18474192 | 0.77 | HSD17B10 (0.47) | HSD17B10GAAHCAR1ALDH1A1HPGD | |
| SCHEMBL17678098 | 0.77 | GAA (0.47) | HSD17B10GAAHCAR1ALDH1A1HPGD | |
| SCHEMBL18136684 | 0.77 | GAA (0.50) | HSD17B10GAAHCAR1ALDH1A1HPGD | |
| SCHEMBL17678351 | 0.77 | GAA (0.47) | HSD17B10GAAHCAR1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | HSD17B10 920/4885GAA 766/4885HCAR1 2842/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | HSD17B10 3245/4885GAA 2041/4885HCAR1 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.